A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has been linked to disease development. A large number of kinase inhibitors are therefore currently under investigation in clinical trials, and so far seven inhibitors have been approved as anti-cancer drugs. In...

Full description

Bibliographic Details
Main Authors:	Fedorov, O, Marsden, B, Pogacic, V, Rellos, P, Müller, S, Bullock, A, Schwaller, J, Sundström, M, Knapp, S
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Insights for the development of specific kinase inhibitors by targeted structural genomics.
by: Fedorov, O, et al.
Published: (2007)

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
by: Pogacic, V, et al.
Published: (2007)

Recently targeted kinases and their inhibitors-the path to clinical trials.
by: Knapp, S, et al.
Published: (2014)

Recently targeted kinases and their inhibitors - the path to clinical trials
by: Knapp, S, et al.
Published: (2014)

Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
by: Bullock, A, et al.
Published: (2009)

Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation
by: Bullock, A, et al.
Published: (2009)

Kinase inhibitor selectivity profiling using differential scanning fluorimetry.
by: Fedorov, O, et al.
Published: (2012)

Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
by: Bullock, A, et al.
Published: (2005)

Structural comparison of human mammalian ste20-like kinases.
by: Record, C, et al.
Published: (2010)

DFG-1 residue controls inhibitor binding mode and affinity, providing a basis for rational design of kinase inhibitor selectivity
by: Schröder, M, et al.
Published: (2020)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
by: Akué-Gédu, R, et al.
Published: (2009)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
by: Miduturu, C, et al.
Published: (2011)

7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
by: Huber, K, et al.
Published: (2012)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65.
by: Cai, B, et al.
Published: (2006)

Structure and regulation of the human Nek2 centrosomal kinase.
by: Rellos, P, et al.
Published: (2007)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
by: Bullock, A, et al.
Published: (2009)

Targeting kinases for the treatment of inflammatory diseases.
by: Müller, S, et al.
Published: (2010)

Synthesis of kinase inhibitors containing a pentafluorosulfanyl moiety
by: Sansook, S, et al.
Published: (2017)

Synthesis of kinase inhibitors containing a pentafluorosulfanyl moiety
by: Sansook, S, et al.
Published: (2017)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
by: Bataille, C, et al.
Published: (2017)

Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf.
by: Alessi, DR, et al.
Published: (1995)

Identification of cyclin-dependent kinase (CDK) 6 as a novel p65 NK-kappaB Ser536 kinase
by: Buss, H, et al.
Published: (2008)

Structure of dystrophia myotonica protein kinase.
by: Elkins, J, et al.
Published: (2009)

Structure of dystrophia myotonica protein kinase.
by: Elkins, J, et al.
Published: (2009)

Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
by: Dixon-Clarke, S, et al.
Published: (2017)

Versatile selective kinase inhibitors: Chemistry and biology of indirubins
by: Gaboriaud-Kolar, N, et al.
Published: (2012)

Cinnamomum iners as Mitogen-Activated Protein Kinase Kinase (MKK1) inhibitor
by: Pang, Kam Lee, et al.
Published: (2009)

Structure and substrate specificity of the Pim-1 kinase
by: Bullock, A, et al.
Published: (2005)

Structure and substrate specificity of the Pim-1 kinase.
by: Bullock, A, et al.
Published: (2005)

Doing more than just the structure-structural genomics in kinase drug discovery.
by: Marsden, B, et al.
Published: (2008)

Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia
by: Yang, Haiyan, et al.
Published: (2020)

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
by: Brault, L, et al.
Published: (2010)

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors
by: Suebsuwong, C, et al.
Published: (2018)

LIM Domain Kinase 1 (LIMK1), Human Kinase Domain; A Target Enabling Package
by: Bullock, A
Published: (2018)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
by: Hellwig, S, et al.
Published: (2012)

Leucettines, a family of pharmacological inhibitors of DYRKs and CLKs kinases derived from the marine sponge Leucettamine B
by: Tahtouh, T, et al.
Published: (2012)

SH2 domains: modulators of nonreceptor tyrosine kinase activity.
by: Filippakopoulos, P, et al.
Published: (2009)

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
by: Grundler, R, et al.
Published: (2009)